PANC-1 |
Function Assay |
84 μM |
24 h |
|
enhances EGFR, HER3 and AKT phosphorylation levels |
22977607 |
BXPC-3 |
Function Assay |
39.86 μM |
24 h |
|
enhances EGFR, HER3 and AKT phosphorylation levels |
22977607 |
PANC-1 |
Function Assay |
84 μM |
24 h |
|
enhances EGFR phosphorylated levels, and the protein levels |
22977607 |
BXPC-3 |
Function Assay |
39.86 μM |
24 h |
|
enhances EGFR phosphorylated levels, and the protein levels |
22977607 |
BXPC-3 |
Function Assay |
39.86 μM |
24 h |
|
induces S arrest (P<0.05) and decreases the number of cells in the G2/M phase |
22977607 |
PANC-1 |
Growth Inhibition Assay |
|
|
|
IC50=83.76±0.19 μM |
22977607 |
BXPC-3 |
Growth Inhibition Assay |
|
|
|
IC50=39.86±1.68 μM |
22977607 |
Jurkat |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=76.7±4.3 % |
23840376 |
DM-3 |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=101.3±2.8 % |
23840376 |
JL-1 |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=98.2±2.2 % |
23840376 |
ZL-34 |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=95.7±6.5 % |
23840376 |
STAV-FCS |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=88.1±8.9 % |
23840376 |
M-14-K |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=81.8±12.9 % |
23840376 |
STAV-AB |
Growth Inhibition Assay |
|
48 h |
|
proportion of live cells=64.4±21.8 % |
23840376 |
LoVo |
Function Assay |
0.05 μM |
72 h |
DMSO |
increases the percentage of cells in the S phase |
23959460 |
HT-29 |
Function Assay |
0.05 μM |
72 h |
DMSO |
increases the percentage of cells in the S phase |
23959460 |
WiDr |
Growth Inhibition Assay |
|
72 h |
DMSO |
IC50=0.019 ± 0.002 μM |
23959460 |
SW1116 |
Growth Inhibition Assay |
|
72 h |
DMSO |
IC50=1.70 ± 0.03 μM |
23959460 |
HCT116 |
Growth Inhibition Assay |
|
72 h |
DMSO |
IC50=0.049 ± 0.013 μM |
23959460 |
SW620 |
Growth Inhibition Assay |
|
72 h |
DMSO |
IC50=1.09 ± 0.01 μM |
23959460 |
LoVo |
Growth Inhibition Assay |
|
72 h |
DMSO |
IC50=0.032 ± 0.002 μM |
23959460 |
HT-29 |
Growth Inhibition Assay |
|
72 h |
DMSO |
IC50=10.07 ± 0.94 μM |
23959460 |
A549/PEM-16 |
Growth Inhibition Assay |
|
96 h |
|
IC50=51.45 μM |
24348854 |
A549/PEM-6.4 |
Growth Inhibition Assay |
|
96 h |
|
IC50=23.39 μM |
24348854 |
A549/PEM-1.6 |
Growth Inhibition Assay |
|
96 h |
|
IC50=5.03 μM |
24348854 |
A549 |
Growth Inhibition Assay |
|
96 h |
|
IC50=1.35 μM |
24348854 |
MSTO-211H |
Cell Viability Assay |
1-10 μg/ml |
72 h |
|
IC50~0.04 μg/ml |
24378576 |
Y-meso14 |
Cell Viability Assay |
1-10 μg/ml |
72 h |
|
IC50>10 μg/ml |
24378576 |
H290 |
Cell Viability Assay |
1-10 μg/ml |
72 h |
|
IC50>10 μg/ml |
24378576 |
H226 |
Cell Viability Assay |
1-10 μg/ml |
72 h |
|
IC50>10 μg/ml |
24378576 |
H1299 |
Growth Inhibition Assay |
|
|
|
IC50=1.84 μM |
24418519 |
H1993 |
Growth Inhibition Assay |
|
|
|
IC50=0.17 μM |
24418519 |
A549 |
Function Assay |
0.1/0.3/0.5/1 μM |
24/48 h |
DMSO |
produces the formation of AVOs in a dose-dependent manner |
24626722 |
A549 |
Cell Viability Assay |
0.1/0.3/0.5/1 μM |
24/48 h |
DMSO |
inhibits cell viability dose and time dependently |
24626722 |
MES04 |
Growth Inhibition Assay |
|
|
|
IC50>100 μM |
24714722 |
MES01 |
Growth Inhibition Assay |
|
|
|
IC50>100 μM |
24714722 |
H2452 |
Growth Inhibition Assay |
|
|
|
IC50>100 μM |
24714722 |
H2052 |
Growth Inhibition Assay |
|
|
|
IC50=0.57±0.34 μM |
24714722 |
211H |
Growth Inhibition Assay |
|
|
|
IC50=0.07±0.01 μM |
24714722 |
H28 |
Growth Inhibition Assay |
|
|
|
IC50=0.07±0.02 μM |
24714722 |
PC9/GR |
Function Assay |
4.94 μM |
72 h |
|
increases p-AKT levels |
24840891 |
PC9/GR |
Function Assay |
4.94 μM |
72 h |
|
increases p-ERK levels |
24840891 |
PC9/GR |
Apoptosis Assay |
4.94 μM |
72 h |
|
induces 19.54﹪ apoptosis |
24840891 |
PC9 |
Apoptosis Assay |
16 nM |
72 h |
|
induces 14.54﹪ apoptosis |
24840891 |
PC9/GR |
Function Assay |
4.94 μM |
72 h |
|
induces S-phase arrest |
24840891 |
PC9 |
Function Assay |
16 nM |
72 h |
|
induces S-phase arrest |
24840891 |
PC9/GR |
Growth Inhibition Assay |
|
72 h |
|
IC50=4.94±0.440 μM |
24840891 |
PC9 |
Growth Inhibition Assay |
|
72 h |
|
IC50=16.05±1.85 nM |
24840891 |
A549 |
Function Assay |
0.1/0.3/1 μM |
48 h |
|
increases the ratio of S-phase population |
24847863 |
A549 |
Apoptosis Assay |
0.1/0.3/1 μM |
48 h |
|
induces apoptosis in a dose dependent manner |
24847863 |
A549 |
Function Assay |
0.1/0.3/1 μM |
48 h |
|
increases the level of phosphorylated Akt in a dose dependent manner |
24847863 |
A549 |
Function Assay |
1 µM |
4/8/12/24/48 h |
|
increases the level of phosphorylated Akt in a time dependent manner |
24847863 |
A549 |
Function Assay |
5 μM |
8 h |
|
increases Mcl-1 ubiquitination levels |
24991768 |
A549 |
Apoptosis Assay |
2.5 μM |
48 h |
|
induces apoptosis |
24991768 |
H1792 |
Function Assay |
2.5/5/10 μM |
48 h |
|
downregulates Mcl-1 |
24991768 |
A549 |
Function Assay |
2.5/5/10 μM |
48 h |
|
downregulates Mcl-1 |
24991768 |
H1792 |
Function Assay |
2.5 μM |
48 h |
|
induces caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage |
24991768 |
A549 |
Function Assay |
2.5 μM |
48 h |
|
induces caspase-9, caspase-3 and poly (ADP-ribose) polymerase (PARP) cleavage |
24991768 |
H1792 |
Function Assay |
2.5/5/10 μM |
48 h |
|
increases Noxa expression significantly |
24991768 |
A549 |
Function Assay |
2.5/5/10 μM |
48 h |
|
increases Noxa expression significantly |
24991768 |
A549 |
Function Assay |
1 μM |
48 h |
|
leads to mitochondrial dysfunction combined with simvastatin |
25096993 |
MSTO-211 |
Function Assay |
1 μM |
48 h |
|
leads to mitochondrial dysfunction combined with simvastatin |
25096993 |
A549 |
Function Assay |
1 μM |
48 h |
|
enhances intracellular ROS production combined with simvastatin |
25096993 |
MSTO-211 |
Function Assay |
1 μM |
48 h |
|
enhances intracellular ROS production combined with simvastatin |
25096993 |
A549 |
Apoptosis Assay |
1 μM |
48 h |
|
enhances caspase-dependent apoptosis combined with simvastatin |
25096993 |
MSTO-211 |
Apoptosis Assay |
1 μM |
48 h |
|
enhances caspase-dependent apoptosis combined with simvastatin |
25096993 |
A549 |
Cell Viability Assay |
1 μM |
48 h |
|
produces a synergistic inhibitory effect on the cell growth combined with simvastatin |
25096993 |
MSTO-211 |
Cell Viability Assay |
1 μM |
48 h |
|
produces a synergistic inhibitory effect on the cell growth combined with simvastatin |
25096993 |
H1299 |
Cell Viability Assay |
1-1000 nM |
72 h |
|
IC50=178 nM |
25145669 |
A549 |
Cell Viability Assay |
1-1000 nM |
72 h |
|
IC50=137 nM |
25145669 |
MG-63 |
Cell Viability Assay |
0.01-100 μM |
72 h |
|
inhibits cell viability dosedependently |
25152399 |
U20S |
Cell Viability Assay |
0.01-100 μM |
72 h |
|
inhibits cell viability dosedependently |
25152399 |
HepG3 |
Function Assay |
10 μM |
48 h |
|
upregulates phosphorylated (p-) MEK1/2 (Ser217/221) and p-ERK1/2 (Thr202/Tyr204) |
25446102 |
HepG3 |
Function Assay |
0.1–100 μM |
48 h |
|
activates cyto-protective autophagy |
25446102 |
HepG3 |
Function Assay |
0.1–100 μM |
48 h |
|
induces p62 downregulation as well as Beclin-1 and LC3B-II upregulation |
25446102 |
HepG2 |
Apoptosis Assay |
0.1–100 μM |
72 h |
|
induces apoptosis slightly at high concerntration |
25446102 |
HepG2 |
Cell Viability Assay |
0.1–100 μM |
72 h |
|
high concentrations of pemetrexed at (10/100 μM) only slightly inhibits HepG2 cell survival |
25446102 |
A459 |
Apoptosis Assay |
4μM |
48 h |
|
induces apoptosis |
25743822 |
A459 |
Function Assay |
1/2/4 μM |
48 h |
|
decreases the levels of p-Akt |
25743822 |
A459 |
Function Assay |
1/2/4 μM |
24/48 h |
|
induces G1 phase arrest in dose- and time dependent manner |
25743822 |
T47D |
Growth Inhibition Assay |
0.234 mM |
72 h |
|
growth inhibition=30﹪ |
25975637 |
HeLa |
Growth Inhibition Assay |
0.234 mM |
72 h |
|
growth inhibition=20﹪ |
25975637 |
A549 |
Growth Inhibition Assay |
0.234 mM |
72 h |
|
growth inhibition=50﹪ |
25975637 |
Vero |
Growth Inhibition Assay |
0.234 mM |
72 h |
|
growth inhibition=20﹪ |
25975637 |
T47D |
Growth Inhibition Assay |
0.234 mM |
48 h |
|
growth inhibition=20﹪ |
25975637 |
HeLa |
Growth Inhibition Assay |
0.234 mM |
48 h |
|
growth inhibition=10﹪ |
25975637 |
A549 |
Growth Inhibition Assay |
0.234 mM |
48 h |
|
growth inhibition=30﹪ |
25975637 |
Vero |
Growth Inhibition Assay |
0.234 mM |
48 h |
|
growth inhibition=10﹪ |
25975637 |
T47D |
Growth Inhibition Assay |
0.234 mM |
24 h |
|
growth inhibition=10﹪ |
25975637 |
HeLa |
Growth Inhibition Assay |
0.234 mM |
24 h |
|
growth inhibition=5﹪ |
25975637 |
A549 |
Growth Inhibition Assay |
0.234 mM |
24 h |
|
growth inhibition=10﹪ |
25975637 |
Vero |
Growth Inhibition Assay |
0.234 mM |
24 h |
|
growth inhibition=5﹪ |
25975637 |
A549 |
Function Assay |
1 μM |
48 h |
|
increases AMPK phosphorylation and a concomitant decrease in AKT and mTOR phosphorylation cotreated with simvastatin |
26334320 |
MSTO-211H |
Function Assay |
1 μM |
48 h |
|
increases AMPK phosphorylation and a concomitant decrease in AKT and mTOR phosphorylation cotreated with simvastatin |
26334320 |
A549 |
Apoptosis Assay |
1 μM |
24 h |
|
induces apoptosis cotreated with simvastatin |
26334320 |
MSTO-211H |
Apoptosis Assay |
1 μM |
24 h |
|
induces apoptosis cotreated with simvastatin |
26334320 |
A549 |
Function Assay |
1 μM |
24 h |
|
enhances autophagy cotreated with simvastatin |
26334320 |
MSTO-211H |
Function Assay |
1 μM |
24 h |
|
enhances autophagy cotreated with simvastatin |
26334320 |
A549 |
Cell Viability Assay |
1 μM |
48 h |
|
enhances simvastatin inhibited viability |
26334320 |
MSTO-211H |
Cell Viability Assay |
1 μM |
48 h |
|
enhances simvastatin inhibited viability |
26334320 |
KB |
Function assay |
|
|
|
IC50 = 0.03 μM |
18680275 |
RT16 |
Antiproliferative assay |
|
|
|
IC50 = 0.042 μM |
18680275 |
D4 |
Antiproliferative assay |
|
|
|
IC50 = 0.06 μM |
18680275 |
KB |
Antiproliferative assay |
|
|
|
IC50 = 0.068 μM |
18680275 |
IGROV1 |
Antiproliferative assay |
|
|
|
IC50 = 0.102 μM |
18680275 |
PC43-10 |
Antiproliferative assay |
|
|
|
IC50 = 0.138 μM |
18680275 |
IGROV1 |
Antiproliferative assay |
|
|
|
IC50 = 0.2 μM |
18680275 |
D4 |
Antiproliferative assay |
|
|
|
IC50 = 0.254 μM |
18680275 |
KB |
Antiproliferative assay |
|
|
|
IC50 = 0.327 μM |
18680275 |
RT16 |
Antiproliferative assay |
|
|
|
IC50 = 0.388 μM |
18680275 |
R2 |
Antiproliferative assay |
|
|
|
IC50 = 0.894 μM |
18680275 |
KB |
Function assay |
|
30 mins |
|
IC50 = 0.03 μM |
19371039 |
R2 |
Function assay |
|
|
|
Ki = 0.096 μM |
20085328 |
R2 |
Function assay |
|
|
|
Ki = 1.54 μM |
20085328 |
KB |
Function assay |
|
|
|
IC50 = 30 μM |
20085328 |
R2 |
Antiproliferative assay |
|
10 to 14 days |
|
IC50 = 0.00494 μM |
21879757 |
R2 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.0132 μM |
21879757 |
RT16 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.042 μM |
21879757 |
D4 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.06 μM |
21879757 |
KB |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.068 μM |
21879757 |
IGROV1 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.102 μM |
21879757 |
PC43-10 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.138 μM |
21879757 |
IGROV1 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.2 μM |
21879757 |
D4 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.254 μM |
21879757 |
KB |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.327 μM |
21879757 |
RT16 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.388 μM |
21879757 |
R2 |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.894 μM |
21879757 |
R2(VC) |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.974 μM |
21879757 |
R2 |
Function assay |
|
|
|
Ki = 0.094 μM |
22243528 |
R2 |
Function assay |
|
|
|
Ki = 2.54 μM |
22243528 |
R2 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.0132 μM |
24111942 |
RT16 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.042 μM |
24111942 |
D4 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.06 μM |
24111942 |
KB |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.068 μM |
24111942 |
PC43-10 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.138 μM |
24111942 |
D4 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.254 μM |
24111942 |
KB |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.327 μM |
24111942 |
RT16 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.388 μM |
24111942 |
MTXRII-OuaR2-4 |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.894 μM |
24111942 |
R2(VC) |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.974 μM |
24111942 |
KB |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.00994 μM |
24256410 |
KB |
Function assay |
|
30 mins |
|
IC50 = 0.01174 μM |
24256410 |
RT16 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.0182 μM |
24256410 |
R2 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.0223 μM |
24256410 |
PC43-10 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.0306 μM |
24256410 |
KB |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.69 μM |
24256410 |
R2/PCFT4 |
Function assay |
|
96 hrs |
|
IC50 = 0.0132 μM |
25234128 |
RT16 |
Function assay |
|
96 hrs |
|
IC50 = 0.042 μM |
25234128 |
D4 |
Function assay |
|
96 hrs |
|
IC50 = 0.06 μM |
25234128 |
KB |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.068 μM |
25234128 |
PC43-10 |
Function assay |
|
96 hrs |
|
IC50 = 0.138 μM |
25234128 |
D4 |
Function assay |
|
96 hrs |
|
IC50 = 0.254 μM |
25234128 |
KB |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.327 μM |
25234128 |
RT16 |
Function assay |
|
96 hrs |
|
IC50 = 0.388 μM |
25234128 |
R2 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.894 μM |
25234128 |
R2 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.974 μM |
25234128 |
KB |
Function assay |
|
1 hr |
|
IC50 = 0.01174 μM |
25602637 |
R2/PCFT4 |
Function assay |
|
96 hrs |
|
IC50 = 0.0132 μM |
25602637 |
RT16 |
Function assay |
|
96 hrs |
|
IC50 = 0.042 μM |
25602637 |
R2 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.042 μM |
25602637 |
KB |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.068 μM |
25602637 |
PC43-10 |
Function assay |
|
96 hrs |
|
IC50 = 0.138 μM |
25602637 |
R2(VC) |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.974 μM |
25602637 |
KB |
Cytotoxicity assay |
|
72 hrs |
|
IC50 = 0.07 μM |
25668494 |
A549 |
Cytotoxicity assay |
|
72 hrs |
|
IC50 = 0.08 μM |
25668494 |
HepG2 |
Cytotoxicity assay |
|
72 hrs |
|
IC50 = 1.26 μM |
25668494 |
R2/PCFT4 |
Function assay |
|
2 mins |
|
K = 0.044 μM |
26317331 |
R2/PCFT4 |
Function assay |
|
2 mins |
|
K = 0.27 μM |
26317331 |
KB |
Antiproliferative assay |
|
72 hrs |
|
IC50 = 0.07 μM |
27017552 |
SW620 |
Antiproliferative assay |
|
72 hrs |
|
IC50 = 0.08 μM |
27017552 |
A549 |
Antiproliferative assay |
|
72 hrs |
|
IC50 = 1.26 μM |
27017552 |
KB |
Function assay |
|
72 hrs |
|
IC50 = 0.07 μM |
28830032 |
SW620 |
Antiproliferative assay |
|
72 hrs |
|
IC50 = 0.09 μM |
28830032 |
MCF7 |
Antiproliferative assay |
|
72 hrs |
|
IC50 = 0.65 μM |
28830032 |
R2/PCFT4 |
Function assay |
|
96 hrs |
|
IC50 = 0.0132 μM |
29425443 |
RT16 |
Function assay |
|
96 hrs |
|
IC50 = 0.042 μM |
29425443 |
D4 |
Function assay |
|
96 hrs |
|
IC50 = 0.06 μM |
29425443 |
KB |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.068 μM |
29425443 |
PC43-10 |
Function assay |
|
96 hrs |
|
IC50 = 0.138 μM |
29425443 |
D4 |
Function assay |
|
96 hrs |
|
IC50 = 0.254 μM |
29425443 |
R2/PCFT4 |
Function assay |
|
2 mins |
|
Ki = 0.259 μM |
29425443 |
KB |
Antiproliferative assay |
|
96 hrs |
|
IC50 = 0.327 μM |
29425443 |
R2 |
Cytotoxicity assay |
|
96 hrs |
|
IC50 = 0.849 μM |
29425443 |
RT16 |
Function assay |
|
96 hrs |
|
IC50 = 0.894 μM |
29425443 |
R2(VC) |
Growth inhibition assay |
|
96 hrs |
|
IC50 = 0.974 μM |
29425443 |
A549 |
Antiproliferative assay |
|
24 hrs |
|
IC50 = 3.31 μM |
29807332 |
MDA-MB-231 |
Antiproliferative assay |
|
24 hrs |
|
IC50 = 3.85 μM |
29807332 |
OVCAR3 |
Antiproliferative assay |
|
24 hrs |
|
IC50 = 6.9 μM |
29807332 |
SGC7901 |
Antiproliferative assay |
|
24 hrs |
|
IC50 = 9.08 μM |
29807332 |
KB |
Function assay |
1 uM |
24 hrs |
|
Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs |
18680275 |
R2 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 10 uM thymidine and 320 uM AICA |
21879757 |
R2 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 60 uM adenosine |
21879757 |
R2 |
Function assay |
|
|
|
Inhibition of GARFTase in chinese hamster R2 cells expressing human PCFT assessed as incorporation of [14C]glycine into [14C]formyl GAR in the presence of 4 uM azaserine |
21879757 |
R2 |
Function assay |
10 uM |
|
|
Inhibition of human PCFT-mediated [3H]MTX uptake ectopically expressed in chinese hamster R2 cells at 10 uM at pH 5.5 to 7.2 |
21879757 |
PC43-10 |
Function assay |
10 uM |
2 mins |
|
Inhibition of human RFC-mediated [3H]MTX uptake in chinese hamster PC43-10 cells at 10 uM after 2 mins relative to control |
21879757 |
KB |
Function assay |
1 uM |
48 hrs |
|
Inhibition of AICARFTase in human KB cells assessed as phosphorylated AMPK at 1 uM after 48 hrs by Western blot analysis |
24256410 |
KB |
Cytotoxicity assay |
|
96 hrs |
|
Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay in presence of adenosine/AICA/thymidine |
24256410 |
KB |
Cell cycle arrest assay |
1 uM |
48 hrs |
|
Cell cycle arrest in human KB cells assessed as accumulation at G1/G0 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control |
24256410 |
KB |
Function assay |
|
48 hrs |
|
Inhibition of AICARFTase in human KB cells assessed as accumulation of ZMP after 48 hrs by HPLC analysis |
24256410 |
R2/PCFT4 |
Function assay |
0.5 uM |
5 mins |
|
Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as intracellular drug level at 0.5 uM at 37 degC at pH 5.5 measured over 5 mins |
26317331 |
TC32 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells |
29435139 |
TC32 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells |
29435139 |
IGROV1 |
Function assay |
|
|
|
Effect on TS protein expression in human IGROV1 cells by Western blot analysis |
30035541 |
IGROV1 |
Function assay |
|
|
|
Effect on DHFR protein expression in human IGROV1 cells by Western blot analysis |
30035541 |
IGROV1 |
Function assay |
|
|
|
Effect on HSP90 protein expression in human IGROV1 cells by Western blot analysis |
30035541 |